Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
企業コードGRAL
会社名Grail Inc
上場日Jun 12, 2024
設立日2020
最高経営責任者「CEO」Mr. Robert (Bob) Ragusa
従業員数1000
証券種類Ordinary Share
決算期末Jun 12
本社所在地1525 O'brien Drive
都市MENLO PARK
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94025
電話番号18336942553
ウェブサイトhttps://grail.com/
企業コードGRAL
上場日Jun 12, 2024
設立日2020
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし